Wednesday, September 4, 2019

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Rolls Out Online Sales of Discrete Powdered Formulation of CBD-Rich Hemp Oil


  • Lexaria Bioscience is an innovator in the field of bioavailable lipophilic active compounds, and it is working to make consumption of certain products through oral ingestion a viable alternative to inhalation
  • A particular focus of the company’s technology is to ensure that cannabinoids can enter the blood stream at speeds comparable to smoking and can be used in a discrete manner
  • Cannabis-infused beverage sales are expected to surpass $1.4 billion by 2024, marking a nearly 15-fold increase over 2018 levels
Drug bio-delivery technology innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched online commercial delivery of the cannabis industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format, making high-quality hemp oil with cannabidiol (CBD) readily available to meet the beverage infusion needs of consumers in the United States.

The company’s August 22 announcement (http://ibn.fm/Ljt7D) states that its ChrgD+ product is powered by Lexaria’s proprietary DehydraTECH(TM) technology for rapid CBD delivery to the user’s bloodstream within 15 minutes – sometimes as fast as two minutes in lab testing.

The rapid bio-delivery of CBD through DehydraTECH provides an avenue for safer, less conspicuous consumption of CBD than inhaling it through smoke or vapor during a critical time when social acceptance of cannabis products is exploding age-old prohibitions but many legislative entities continue to struggle with regulatory issues on behalf of the public welfare.

ChrgD+ has been available in a limited number of retail stores throughout the western United States, but the announcement that it is now available via commercial web delivery to locations where it can be legally consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without having to travel. Limited-time promotional offers and product updates are also available through the site.

Each serving of ChrgD+ weighs just two grams, making it easy for a consumer to carry multiple servings in a shirt pocket or athletic wear while on the go. The multi-spectrum oil-based powder can be poured innocuously into any hot or cold beverage, and every package contains a manufacturing batch code that makes it simple for consumers to browse lab test results for the actual potency of the package’s ingredients (which contain no THC) as part of Lexaria’s push for transparency.

DehydraTECH technology provides the added benefit of gently removing unpleasant cannabis flavors, so ChrgD+ is able to avoid the artificial flavors or sweeteners that other products may use to mask the strong flavors and aromas inherent to hemp oil.

These innovations are examples of Lexaria’s ongoing mission to enhance the “speed of action, flavor and gastro-intestinal delivery of orally-administered products,” particularly those that utilize cannabinoids, nicotine and ibuprofen.

Zenith Global’s industry analysts predict that the U.S. market for cannabis- and hemp-infused drinks will reach more than $1.4 billion by 2024, almost 15-times the 2018 level, as part of an overall trend toward life-enhancing practices that focus on alternatives to traditional medicines and recreational products, including alcoholic beverages and tobacco products (http://ibn.fm/V6ucn).

With the federal legalization of edible cannabis products only a month away in Canada, Lexaria is also preparing to roll out DehydraTECH-licensed products in collaboration with alcohol-free beer, wine and adult format beverage maker Hill Street Beverage Company Inc. (TSX.V: BEER) on a first-time business-to-business (B2B) basis between Canada’s licensed producers and other businesses licensed by Health Canada to make cannabis-infused edibles. The as-yet unnamed new brand will feature processed tetrahydrocannabinol (THC) and/or CBD powder from cannabis or its less chemically psychoactive hemp variant as part of the companies’ efforts to build production in a new market space.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html